Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FB1006 in ALS
NCT05923905Phase 4Recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Jan 2023
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of FB1006 in amyotrophic lateral sclerosis (ALS), sponsored by Peking University Third Hospital. Started Jan 2023; status: recruiting.
02
Drugs
FB1006
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05923905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05923905.